Health Catalyst, Inc. (NASDAQ:HCAT) Position Raised by Impax Asset Management Group plc

Impax Asset Management Group plc lifted its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 7.7% in the 4th quarter, Holdings Channel reports. The fund owned 2,750,000 shares of the company’s stock after buying an additional 195,525 shares during the period. Impax Asset Management Group plc’s holdings in Health Catalyst were worth $19,442,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of HCAT. Harbor Capital Advisors Inc. increased its holdings in shares of Health Catalyst by 21.3% during the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares during the period. Creative Planning grew its holdings in Health Catalyst by 13.2% during the third quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after acquiring an additional 2,486 shares during the period. Legato Capital Management LLC grew its stake in shares of Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock worth $622,000 after purchasing an additional 3,171 shares during the last quarter. Quest Partners LLC bought a new position in shares of Health Catalyst in the third quarter valued at $34,000. Finally, SG Americas Securities LLC raised its position in shares of Health Catalyst by 21.7% during the fourth quarter. SG Americas Securities LLC now owns 27,382 shares of the company’s stock worth $194,000 after purchasing an additional 4,874 shares during the period. 85.00% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Jason Alger sold 19,599 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the transaction, the chief financial officer now owns 86,712 shares of the company’s stock, valued at approximately $721,443.84. The trade was a 18.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Benjamin Landry sold 19,268 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the completion of the sale, the general counsel now directly owns 72,250 shares in the company, valued at $601,120. This trade represents a 21.05 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 87,610 shares of company stock valued at $664,043. Company insiders own 2.50% of the company’s stock.

Health Catalyst Trading Down 4.2 %

Shares of HCAT stock opened at $5.01 on Tuesday. Health Catalyst, Inc. has a 12 month low of $4.96 and a 12 month high of $9.24. The company has a market cap of $304.85 million, a PE ratio of -3.71 and a beta of 1.34. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $6.19 and its two-hundred day moving average is $7.29.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on HCAT shares. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research report on Wednesday, January 8th. Wells Fargo & Company reduced their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Citigroup lowered their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Piper Sandler cut their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada decreased their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and an average target price of $10.20.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.